Novavax Inc (NVAX) has a current Price-to-Book (P/B) ratio of -7.39. Compared to its 3-year average P/B ratio of -0.41, the current P/B ratio is approximately 1714.05% higher. Relative to its 5-year average P/B ratio of 4.94, the current P/B ratio is about -249.79% higher. Novavax Inc (NVAX) has a Forward Free Cash Flow (FCF) yield of approximately -33.12%. Compared to its 3-year average FCF yield of -57.42%, the current FCF yield is approximately -42.32% lower. Relative to its 5-year average FCF yield of -39.53%, the current FCF yield is about -16.21% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NVAX competitors is 6.13, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX.O) exhibits a P/S ratio of 2.09, which is -65.86% above the industry average. Given its robust revenue growth of 66.61%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NVAX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NVAX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NVAX currently overvalued or undervalued?

What is Novavax Inc (NVAX) fair value?

NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Novavax Inc (NVAX) is between 8.95 to 24.47 according to relative valuation method.

How does NVAX's valuation metrics compare to the industry average?

The average P/S ratio for NVAX's competitors is 6.13, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX) exhibits a P/S ratio of 2.09, which is -65.86% above the industry average. Given its robust revenue growth of 66.61%, this premium appears sustainable.

What is the current P/B ratio for Novavax Inc (NVAX) as of Mar 02 2026?

As of Mar 02 2026, Novavax Inc (NVAX) has a P/B ratio of -7.39. This indicates that the market values NVAX at -7.39 times its book value.

What is the current FCF Yield for Novavax Inc (NVAX) as of Mar 02 2026?

As of Mar 02 2026, Novavax Inc (NVAX) has a FCF Yield of -33.12%. This means that for every dollar of Novavax Inc's market capitalization, the company generates -33.12 cents in free cash flow.

What is the current Forward P/E ratio for Novavax Inc (NVAX) as of Mar 02 2026?

As of Mar 02 2026, Novavax Inc (NVAX) has a Forward P/E ratio of -9.03. This means the market is willing to pay $-9.03 for every dollar of Novavax Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Novavax Inc (NVAX) as of Mar 02 2026?

As of Mar 02 2026, Novavax Inc (NVAX) has a Forward P/S ratio of 2.09. This means the market is valuing NVAX at $2.09 for every dollar of expected revenue over the next 12 months.

NVAX Valuation